A COST-EFFECTIVENESS ANALYSIS OF ABATACEPT, TOCILIZUMAB, AND TNF-INHIBITOR COMPARED WITH RITUXIMAB AS A SECOND-LINE THERAPY FOR TREATMENT OF RHEUMATOID ARTHRITIS

被引：0
|
作者：
Huoponen, S. [1 ]
Aaltonen, K. J. [1 ]
Joensuu, J. T. [1 ]
Rutanen, J. [2 ]
Relas, H. [3 ]
Taimen, K. [4 ]
Puolakka, K. [5 ]
Sokka, T. [6 ]
Nordstrom, D. [3 ]
Blom, M. [1 ]
机构：
[1] Univ Helsinki, Helsinki, Finland
[2] Lahti Cent Hosp, Lahti, Finland
[3] Helsinki Univ Cent Hosp, Helsinki, Finland
[4] Turku Univ, Cent Hosp, Turku, Finland
[5] South Karelia Cent Hosp, Lappeenranta, Finland
[6] Jyvaskyla Cent Hosp, Jyvaskyla, Finland
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.1110
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMS43
引用
收藏
页码：A538 / A538
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of rituximab therapy for rheumatoid arthritis: A Pan-European analysis
    Kielhorn, A
    Rubbert, A
    Porter, D
    De Vita, S
    Brown, B
    Aristides, M
    Aultman, R
    Jost, F
    [J]. VALUE IN HEALTH, 2006, 9 (03) : A27 - A27
  • [22] Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia
    Whalen, John
    Stillman, Ipek
    Ambavane, Apoorva
    Felber, Eugene
    Makenbaeva, Dinara
    Bolinder, Bjorn
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (05) : 445 - 461
  • [23] Pembrolizumab as second-line therapy of hepatocellular carcinoma: A cost-effectiveness analysis
    Chan, S.
    Chiang, C.
    Lee, S.
    Wong, I.
    Choi, H.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S174 - S174
  • [24] COMPARISON OF THE EFFICACY OF SECOND TNF INHIBITOR VERSUS ALTERNATIVE BIOLOGICAL AGENT (RITUXIMAB/TOCILIZUMAB/ABATACEPT) AFTER SECONDARY FAILURE TO INITIAL ANTI TNF THERAPY IN RHEUMATOID ARTHRITIS A RETROSPECTIVE OBSERVATIONAL ANALYSIS
    Shipa, M. R. A.
    Di Cicco, M.
    Roussou, E.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1012 - 1012
  • [25] Modelling of the cost-effectiveness of rituximab for treatment of rheumatoid arthritis in Italy
    De, VS
    Giuliani, G
    Diamantopoulos, A
    Brown, B
    Kielhorn, A
    [J]. VALUE IN HEALTH, 2006, 9 (03) : A26 - A26
  • [26] Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain
    Peral, Carmen
    Cordido, Fernando
    Gimeno-Ballester, Vicente
    Mir, Nuria
    Sanchez-Cenizo, Laura
    Rubio-Rodriguez, Dario
    Rubio-Terres, Carlos
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2020, 20 (01) : 105 - 114
  • [27] Cost-effectiveness of biological therapy compared with methotrexate in the treatment for rheumatoid arthritis in Colombia
    Carolina Valle-Mercado
    Maria-Fernanda Cubides
    Monica Parra-Torrado
    Diego Rosselli
    [J]. Rheumatology International, 2013, 33 : 2993 - 2997
  • [28] Cost-effectiveness of biological therapy compared with methotrexate in the treatment for rheumatoid arthritis in Colombia
    Valle-Mercado, Carolina
    Cubides, Maria-Fernanda
    Parra-Torrado, Monica
    Rosselli, Diego
    [J]. RHEUMATOLOGY INTERNATIONAL, 2013, 33 (12) : 2993 - 2997
  • [29] Modeling the Cost-effectiveness of Rituximab Use Compared to Tumor Necrosis Factor Inhibitors (anti-TNF) Agents as a Second-line Therapy in Patients with Rheumatoid Arthritis (RA) in Quebec, Canada Using RHUMADATA Registry Data
    Lopatina, Elena
    Choquette, Denis
    Coupal, Louis
    Marshall, Deborah
    [J]. JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 882 - 883
  • [30] MODELING THE COST-EFFECTIVENESS OF RITUXIMAB USE COMPARED TO TUMOR NECROSIS FACTOR INHIBITORS (ANTI-TNF) AGENTS AS A SECOND-LINE THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IN QUEBEC, CANADA USING RHUMADATA REGISTRY DATA
    Lopatina, E.
    Marshall, D. A.
    Coupal, L.
    Choquette, D.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A147 - A147
12345